Home

Our Technology

Innovative Chemistry
Transformative Therapies

About us

What We Do

We’re a biotech company committed to stemming the prescription drug abuse epidemic.

Investment

Long Term
Opportunity

Events & Presentations

Ensysce Corporate Overview Find Out More

Events & Presentations

Special Meeting of Stockholders Find Out More

Events & Presentations

2022 Annual Meeting of Stockholders Find Out More
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR Read More
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds Read More
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference Read More
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain Read More
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR Read More

Our Team

Brilliant minds
and vision

We’re proud to say our team is made up of just that — people and minds both driven by passion and full of potential. Our company is led by a team of executives and directors with vast experience and proven track records in pain, drug development and commercialization.

D. Lynn Kirkpatrick, PhD

Chief Executive Officer

Dave Humphrey

Chief Financial Officer

Bill Schmidt, PhD

Chief Medical Officer.

Jeffrey Millard, PhD

Chief Operating Officer

Geoff Birkett

Chief Commercial Officer

Linda Pestano, PhD

Chief Development Officer